Related Experiment Video
Updated: Aug 23, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
The Correlation Between CD44 and Angiogenesis in Oral Squamous Cell Carcinoma Induced in Buccal Pouch in Syrian
Reham Alsafadi1, Ahmad Manadili1
1Department of Oral Pathology, Faculty of Dentistry, Damascus University, Syria.
Background:
Angiogenesis with radiotherapy is a significant focus of recent studies to confirm the importance of combined treatments, as vascular control can have a great therapeutic target. Vascular endothelial growth factor is the key mediator of angiogenesis in cancer. In addition, some studies suggest the value of CD44 as a potential early marker of angiogenesis.
Objectives:
Investigating the expression of vascular endothelial growth factor (VEGF) and CD44 in oral squamous cell carcinoma (OSCC) after inducing it in hamsters then undergoing radiotherapy and comparing outcomes before and after therapy to verify changes of these markers.
Materials & Methods:
an experimental study consisted of 18 samples of OSCC which induced in right buccal pouch of hamsters (group1) and 18 samples of OSCC which induced in the same way and were exposed to radiation therapy (group2), Biopsies were taken and fixed with formalin, paraffin waxed in conventional H&E and immunostained with monoclonal anti-VEGF and anti-CD44.
Results:
our findings didn't reveal a statistically significant difference in the expression of VEGF(p =0.342) and CD44 (p=0.187) between group1 & group 2. moreover, we found tumor cells which weren't affected and resistant to radiotherapy, also revealed positive expression of VEGF & CD44, otherwise, we noticed Pearson coefficient was a significant correlation that indicated to a moderate relation.
Conclusion:
cancerous cells that showed a high expression of these markers, give elevated radiosensitivity and resist the treatment. Subsequently, we assure the importance of applying anti-VEGF and/or anti-CD44 as a supportive therapy with radiation therapy.
